3rd ESTRO Forum 2015 S799 joined this inter-comparison. Almost every region of Italy was represented. In figure 1, the distribution of the PTV gEUD and of the MLDeq2Gy PI are shown. The dot line is the minimum PI required value; the spread of the data intra-institution and inter-institution is visible. The PI related to the rib max dose shows a significant correlation (p=0.01) with the use of CyberKnife versus Linac or Tomo. Almost all centers have values above the minimum required index but all of them, except for CyberKnife, show performances below the reference one, indicating a weak consideration of this constraint. Otherwise, for the PI of spinal cord max dose, all center are above the dot line. Any correlation was found between performances and the participants expertise or for other technical parameters. Figure 1: distribution of gEUD among the centres and of MLDeq2Gy performance index. The dot line is the minimum required value.
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Conclusions:
A notable inter-institutional difference in terms of gEUD and general planning strategies was found. For a multi-institutional study perspective, detailed dose specification and planning strategies based on collaboration and discussion are mandatory. Purpose/Objective: 4DCT and CBCT imaging in radiotherapy delivers a small priming dose, which is ignored in treatment planning, despite evidence that the size and sequence of partial fractions affects cell survival 1,2 . The delay between imaging and treatment may be minutes or days for CBCT and 4DCT respectively. There is a trend towards increasing use of these imaging modalities as they enable more accurate delivery of therapeutic dose. The biological effect of an imaging partial fraction in addition to the therapeutic dose on cell survival is uncertain. We report here on the effect of an imaging dose prior to a therapeutic dose on cell survival in two human cancer cell lines and one normal human cell line. The effects are examined for current typical imaging dose levels and a projection is made of the effects on cell survival of an increase in the imaging dose. Materials and Methods: In-vitro clonogenic assays were used to obtain experimental data for non-small cell lung cancer (NCI-H460), melanoma (MM576) and a normal (HUVEC) cell lines. The 4DCT was performed on a Toshiba Aquilon CT with a Varian RPM motion management system and the CBCT on a 6MV proton beam from a Varian Novalis linac with a kV-cone beam system. The therapeutic dose D 2 was delivered after time t using the Varian Novalis. An expression for cell survival S was derived using the Lea-Catcheside formalism, with and without the imaging dose D 1 . The effect on cell survival of increasing the imaging dose to a projected 10, 20 and 50 cGy was modelled. Results: For the two human cancer cell lines considered in this study, D 1 (measured to be 0, 0.60cGy [CBCT] or 14.0 cGy [4DCT]) given prior to a D 2 (0, 2 or 4 Gy), has no measurable effect on cell survival, irrespective of the time delay. The theoretical analysis confirmed the experimental findings for these imaging doses, that an additional partial fraction dose from CBCT or 4DCT is not likely to affect tumour control significantly as the cell survival was predicted to decrease by 2-3% for 4DCT. However, if the imaging dose is increased to 20 and 50 cGy, it is predicted the clonogenic survival would decrease by 6 and 15% respectively for the cancer cell lines. This decrease was predicted to be smaller for the normal cell line (4 and 6% for 20 and 50 cGy respectively).
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Conclusions:
This study indicates that, at the current dose levels, it is not necessary to consider the imaging dose from 4DCT or CBCT in the planning of radiotherapy treatment. However, if the imaging dose is increased then imaging dose may need to be included in treatment planning. Purpose/Objective: While conventionally fractionated radiotherapy (CFRT) has proven ineffective in curing nonsmall-cell lung cancer (NSCLC), promising results have been obtained with stereotactic body radiotherapy (SBRT) employing few high-dose fractions. Extreme hypofractionation might however compromise the treatment outcome in hypoxic tumours given the reduced possibility for reoxygention between fractions. An alternative approach could involve schedules employing fewer fractions than CFRT, but more than in a typical SBRT treatment while partly escalating the fractional dose. It was the purpose of this study to investigate heterogeneous fractionation patterns with respect to the dose per fraction, taking into account the spatial and dynamic aspects of the tumour oxygenation and the effect of accelerated repopulation of tumour cells in treatments extending over several weeks. Materials and Methods: Three-dimensional in silico tumours with heterogeneous oxygenation were simulated based on previous calculations from intervessel distance distributions. Homogeneous dose delivery was simulated employing 2 Gy per fraction as baseline and partly escalating the dose to 3 and 4 Gy per fraction corresponding to fractions delivered prior to or directly following a short interruption of the treatment as represented by the weekends. Survival was assessed on voxel level with the linear-quadratic (LQ) model taking into account the dose-modifying effect of the oxygenation. The effect of accelerated repopulation was incorporated assuming a kick-off time of 14 days and a potential doubling time of 5 days for NSCLC. Local control was evaluated as tumour control probability (TCP) through a Poisson-based model and dose-response curves were generated by systematically varying the total dose. Results: For tumours with a negligible level of spread-out hypoxia (left panel of Figure 1 ) and assuming that accelerated repopulation starts after two weeks, partly increasing the fractional dose could substantially improve local control even if no reoxygenation takes place. If however the effects of repopulation are neglected and the hypoxia is geometrically concentrated instead of being spread out throughout the tumour, the impact of reoxygenation is far more important than partly escalating the fractional dose, even for small hypoxic fractions (right panel of Figure 1 ).
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Conclusions:
Heterogeneous fractionation might ensure high levels of control in well-oxygenated tumours even when inter-fraction reoxygenation cannot be assumed. For tumours with more concentrated hypoxia, moderately heterogeneous fractionation patterns cannot counteract the increased radioresistance of tumour hypoxia.
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The dosimetric effect of interfraction motion on the duodenum in pancreatic radiotherapy A. Witztum 1 , S. Warren 1 , D. Holyoake 1 , M. Partridge 1 , S. Mukherjee 1 , M.A. Hawkins 1 1 CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, United Kingdom Purpose/Objective: Dose given to the tumour in patients with locally-advanced pancreatic cancer (LAPC) is limited by normal tissue toxicity in the gastrointestinal tract. The close proximity of the duodenum to the target volume therefore makes studying the link between duodenal dose and treatment outcome of interest. This study investigates the effect of changes in size and position of the duodenum throughout treatment on dosimetric parameters. Materials and Methods: Three patients from the ARCII trial (EudraCT 2008-006302-42) treating LAPC with chemoradiotherapy were chosen for this study. CBCTs from fractions 6, 12, 18 and 24 were fused with the planning CT using a bony and soft tissue match. The duodenum was contoured on the planning CT and each CBCT by a single physician. The contours were copied to the ARCII trial 3D conformal plan prescribing 50.4Gy in 28 fractions to the PTV with a subsequent boost of 9Gy in 5 fractions to a smaller PTV for a total of 59.4Gy. The total volume of the duodenum and the percentage of the duodenum outside of the PTV (% out) were recorded together with V35 and V55 from the duodenum dose surface histograms (DSHs). Results: The volume of the duodenum on the planning CT and the range of duodenum volumes over the 4 CBCT contours were 86.6cm 3 (56.7 -71.9), 41.6cm 3 (45.9 -80.6) and 93.1cm 3 (76.7 -132.7) for patients 1, 2 and 3 respectively. Figure 1 shows large interfraction variation in the volume of the duodenum. There is also variation in the percentage of the duodenum located outside the PTV. It is also seen that as more of the duodenum is found outside the PTV, the dose volume metrics of the duodenum are reduced. There is no such link to absolute volume change.
